
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

Dated May 16, 2018

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street

Victoria, British Columbia

V8Z 7X8

(250) 708-4272

(Address and telephone number of registrant's principal executive offices)

Indicate by check mark whether the registrant files of will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

This Form 6-K is hereby filed and incorporated by reference in the registrant's Registration Statement on Form F-10 (File No. 333-222413).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 16, 2018

Aurinia Pharmaceuticals Inc.

By: /s/ Dennis Bourgeault

Name: Dennis Bourgeault

Title: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Document</u>
99.1	Notice of Annual General Meeting of Shareholders
99.2	Notice and Access Notice of Annual General Meeting of Shareholders
99.3	Information Circular
99.4	Form of Proxy

Exhibits 99.1, 99.2, 99.3 and 99.4 included with this report on Form 6-K are hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or supplemented.

AURINIA PHARMACEUTICALS INC.

Notice of Annual General Meeting of Shareholders

NOTICE is hereby given that the Annual General Meeting (the “**Meeting**”) of shareholders of Aurinia Pharmaceuticals Inc. (the “**Company**”) will be held at 1200 Waterfront Centre, 200 Burrard Street, Vancouver, British Columbia on Thursday, June 21, 2018, at 9:00 AM, Pacific Time, for the following purposes:

1. to fix the number of directors at eight;
2. to elect the directors for the ensuing year;
3. to receive the audited consolidated financial statements of the Company for the financial year ended December 31, 2017, and the report of the auditors thereon;
4. to re-appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company and to authorize the Company’s audit committee to fix the auditors’ remuneration; and
5. to transact such further and other business as may properly be brought before the Meeting or any adjournment thereof.

Management of the Company is soliciting proxies on the accompanying form of proxy (the “**Proxy**”). Shareholders who are unable to attend the Meeting are requested to complete, date, sign and return the Proxy so that as large a representation of shareholders as possible may be had at the Meeting. Specific details of the matters being put before the Meeting are set forth in more detail in the accompanying management information circular.

The board of directors (the “**Board**”) has determined that only holders of record of the common shares of the Company at the close of business on May 4, 2018 will be entitled to vote in respect of the items set out in this notice of meeting at the Meeting. The Board has also determined 9:00 AM, Pacific Time, on Tuesday, June 19, 2018 as the time before which proxies to be used or acted upon at the Meeting or any adjournment thereof must be deposited with the Company’s transfer agent. Failure to properly complete or deposit a Proxy may result in its invalidation.

DATED this 8th day of May, 2018.

BY ORDER OF THE BOARD

(signed) “Richard M. Glickman”

Richard M. Glickman
Chairman and Chief Executive Officer



AURINIA PHARMACEUTICALS INC.

Notice of Annual General Meeting of Shareholders

Date:	June 21, 2018
Time:	9:00 a.m. (Pacific Time)
Place:	1200 Waterfront Centre 200 Burrard Street Vancouver, British Columbia V7X 1T2

AGENDA

1. Election of Directors: to fix the number of directors at eight and to elect directors to hold office until the next annual meeting of shareholders. See "Election of Directors" in the Management Information Circular for details.
2. Financial Statements and Auditors' Report: to receive the audited consolidated financial statements for the financial year ended December 31, 2017, together with the auditor's report thereon.
3. Appointment of Auditors: to re-appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors until the next annual meeting of shareholders, and to authorize Aurinia Pharmaceuticals Inc.'s ("Aurinia") Audit Committee to fix their remuneration. See "Appointment and Remuneration of Auditors" in the Management Information Circular for details.
4. Other Business: to transact such further business which properly comes before the meeting or any adjournment.

Notice-and-access: This Notice of Meeting is prepared under the notice-and-access rules that came into effect on February 11, 2013 under National Instrument 54-101 *Communication with Beneficial Owners of Securities of a Reporting Issuer*. Notice-and-access is a set of rules intended to reduce the volume of materials that must be physically mailed to shareholders by allowing issuers to post the Management Information Circular and additional materials online. Aurinia has elected to use procedures known as "stratification" and will provide a paper copy of the Management Information Circular to some but not all of the shareholders. In relation to the meeting, the registered shareholders will receive a paper copy of the notice of meeting, the Management Information Circular, and the form of proxy. Beneficial shareholders will receive a paper copy of the notice of meeting and a voting instruction form. In addition, a paper copy of this Management Information Circular will be mailed to those beneficial shareholders who have previously requested to receive a paper copy. Materials may be delivered electronically to shareholders. Please call Computershare Investor Services Inc. ("Computershare"), the transfer agent of Aurinia, toll free at 1-866-964-0492 if you have any questions about notice-and-access.

Management Information Circular: The Management Information Circular, audited financial statements and management discussion and analysis and additional materials are available on Aurinia's pages on SEDAR at www.sedar.com on EDGAR at www.sec.gov and on Aurinia's website at www.auriniapharma.com. Shareholders are reminded to review these online materials before voting. Shareholders may obtain paper copies by: a) calling Aurinia toll free at 1-844-744-2487; or b) emailing Aurinia at agm@auriniapharma.com. In addition, Aurinia will host the meeting materials at www.auriniapharma.com. A request for paper copies should be sent so that it is received by end of business on June 5, 2018 in order to allow sufficient time for the shareholder to receive the paper copy and return the proxy by its due date.

Voting Instruction Form: If you are not attending the meeting, please sign, date and return the enclosed voting instruction form. If you or a person you designate plan to attend the meeting, you must appoint yourself or that person as proxy to have voting rights at the meeting. Use the voting instruction form provided by your intermediary (bank, trust company or broker) and return it as early as practicable to ensure that they can complete a form of proxy before 9:00 am on June 19, 2018.

Voting: You may vote or appoint a proxy by providing the voting instruction form to your intermediary, which then, as registered shareholder, submits your vote or proxy appointment to Aurinia's transfer agent, Computershare Investor Services Inc.

Further information on voting can be found under the headings "Appointment and Revocation of Proxies" and "Non-Registered Shareholders" in the Information Circular.

Edmonton, Alberta
May 8, 2018

BY ORDER OF THE BOARD
(signed) "Richard M. Glickman"

Richard M. Glickman
Chairman and Chief Executive Officer



**AURINIA PHARMACEUTICALS INC.
NOTICE OF ANNUAL GENERAL MEETING
OF SHAREHOLDERS
TO BE HELD ON
June 21, 2018
and
MANAGEMENT INFORMATION CIRCULAR
Dated May 8, 2018**

AURINIA PHARMACEUTICALS INC.

Notice of Annual General Meeting of Shareholders

NOTICE is hereby given that the Annual General Meeting (the “**Meeting**”) of shareholders of Aurinia Pharmaceuticals Inc. (the “**Company**”) will be held at 1200 Waterfront Centre, 200 Burrard Street, Vancouver, British Columbia on Thursday, June 21, 2018, at 9:00 AM, Pacific Time, for the following purposes:

1. to fix the number of directors at eight;
2. to elect the directors for the ensuing year;
3. to receive the audited consolidated financial statements of the Company for the financial year ended December 31, 2017, and the report of the auditors thereon;
4. to re-appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company and to authorize the Company’s audit committee to fix the auditors’ remuneration; and
5. to transact such further and other business as may properly be brought before the Meeting or any adjournment thereof.

Management of the Company is soliciting proxies on the accompanying form of proxy (the “**Proxy**”). Shareholders who are unable to attend the Meeting are requested to complete, date, sign and return the Proxy so that as large a representation of shareholders as possible may be had at the Meeting. Specific details of the matters being put before the Meeting are set forth in more detail in the accompanying management information circular.

The board of directors (the “**Board**”) has determined that only holders of record of the common shares of the Company at the close of business on May 4, 2018 will be entitled to vote in respect of the items set out in this notice of meeting at the Meeting. The Board has also determined 9:00 AM, Pacific Time, on Tuesday, June 19, 2018 as the time before which proxies to be used or acted upon at the Meeting or any adjournment thereof must be deposited with the Company’s transfer agent. Failure to properly complete or deposit a Proxy may result in its invalidation.

DATED this 8th day of May, 2018.

BY ORDER OF THE BOARD

(signed) “Richard M. Glickman”

Richard M. Glickman
Chairman and Chief Executive Officer

PART 1 VOTING INFORMATION 1

- [1.1 SOLICITATION OF PROXIES](#) 1
- [1.2 APPOINTMENT AND REVOCATION OF PROXIES](#) 1
- [1.3 REGISTERED SHAREHOLDERS](#) 1
- [1.4 NON-REGISTERED SHAREHOLDERS](#) 1
- [1.5 DESCRIPTION OF THE COMPANY](#) 2
- [1.6 VOTING OF PROXIES](#) 2
- [1.7 VOTING SHARES AND PRINCIPAL HOLDERS THEREOF](#) 2
- [1.8 NOTICE AND ACCESS](#) 2

PART 2 BUSINESS OF THE MEETING 3

- [2.1 ELECTION OF DIRECTORS](#) 3
 - [2.1.1 Corporate Cease Trade Orders, Bankruptcies, Penalties or Sanctions](#) 6
 - [2.1.2 Directors' Attendance at Board and Committee Meetings](#) 7
 - [2.1.3 Other Board Membership](#) 8
 - [2.1.4 Directors' and Officers' Insurance and Indemnification](#) 8
- [2.2 PRESENTATION OF FINANCIAL STATEMENTS AND AUDITOR'S REPORT](#) 8
- [2.3 APPOINTMENT AND REMUNERATION OF AUDITORS](#) 8

PART 3 STATEMENT OF EXECUTIVE COMPENSATION 10

- [3.1 COMPENSATION OF EXECUTIVES](#) 10
 - [3.1.1 Compensation Discussion and Analysis](#) 10
 - [3.1.2 Managing Compensation Risk](#) 12
 - [3.1.3 Performance Graph](#) 14
 - [3.1.4 Anti-Hedging Protection](#) 15
 - [3.1.5 Summary Compensation Table](#) 16
 - [3.1.6 Narrative Discussion of Compensation](#) 17
 - [3.1.7 Incentive Plan Awards](#) 21
- [3.2 COMPENSATION OF DIRECTORS](#) 23
- [3.3 EQUITY COMPENSATION PLAN](#) 25
 - [3.3.1 Stock Option Plan](#) 25
 - [3.3.2 Pension Plan Benefits](#) 27
- [3.4 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS](#) 27
- [3.5 INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS](#) 27

PART 4 REPORT ON CORPORATE GOVERNANCE AND OTHER ITEMS 28

- [4.1 COMMITTEES OF THE BOARD](#) 28
[The Board has three standing committees: the Audit Committee, Governance & Nomination Committee and the Compensation Committee. The following are descriptions of the three standing committees of the Board:](#) 28
- [4.2 INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS](#) 28
- [4.3 SHAREHOLDER PROPOSALS](#) 29
- [4.4 ADDITIONAL INFORMATION](#) 29
- [4.5 APPROVAL BY DIRECTORS](#) 29

APPENDIX "A" - STATEMENT OF CORPORATE GOVERNANCE PRACTICES
APPENDIX "B" - MANDATE OF THE BOARD OF DIRECTORS



8th Floor, 100 University Avenue
Toronto, Ontario M5J 2Y1
www.computershare.com

Security Class

Holder Account Number

Fold

Form of Proxy - Annual General Meeting to be held on Thursday, June 21, 2018

This Form of Proxy is solicited by and on behalf of Management.

Notes to proxy

1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any adjournment or postponement thereof. If you wish to appoint a person or company other than the persons whose names are printed herein, please insert the name of your chosen proxyholder in the space provided (see reverse).
2. If the securities are registered in the name of more than one owner (for example, joint ownership, trustees, executors, etc.), then all those registered should sign this proxy. If you are voting on behalf of a corporation or another individual you must sign this proxy with signing capacity stated, and you may be required to provide documentation evidencing your power to sign this proxy.
3. This proxy should be signed in the exact manner as the name(s) appear(s) on the proxy.
4. If this proxy is not dated, it will be deemed to bear the date on which it is mailed by Management to the holder.
5. **The securities represented by this proxy will be voted as directed by the holder, however, if such a direction is not made in respect of any matter, this proxy will be voted as recommended by Management.**
6. The securities represented by this proxy will be voted in favour or withheld from voting or voted against each of the matters described herein, as applicable, in accordance with the instructions of the holder, on any ballot that may be called for and, if the holder has specified a choice with respect to any matter to be acted on, the securities will be voted accordingly.
7. This proxy confers discretionary authority in respect of amendments or variations to matters identified in the Notice of Meeting or other matters that may properly come before the meeting or any adjournment or postponement thereof.
8. This proxy should be read in conjunction with the accompanying documentation provided by Management.

Fold

Proxies submitted must be received by 9:00 am, Pacific Time, on Tuesday, June 19, 2018

VOTE USING THE TELEPHONE OR INTERNET 24 HOURS A DAY 7 DAYS A WEEK!



To Vote Using the Telephone

- Call the number listed BELOW from a touch tone telephone.

1-866-732-VOTE (8683) Toll Free



To Vote Using the Internet

- Go to the following web site:
www.investorvote.com
- **Smartphone?**
Scan the QR code to vote now.



If you vote by telephone or the Internet, DO NOT mail back this proxy.

Voting by mail may be the only method for securities held in the name of a corporation or securities being voted on behalf of another individual.

Voting by mail or by Internet are the only methods by which a holder may appoint a person as proxyholder other than the Management nominees named on the reverse of this proxy. Instead of mailing this proxy, you may choose one of the two voting methods outlined above to vote this proxy.

To vote by telephone or the Internet, you will need to provide your CONTROL NUMBER listed below.

CONTROL NUMBER



Appointment of Proxyholder

I/We being holder(s) of Aurinia Pharmaceuticals Inc. hereby appoint(s): **Richard Glickman**, the Chief Executive Officer and a director of the Company, or failing him, **Dennis Bourgeault**, the CFO of the Company

OR

Print the name of the person you are appointing if this person is someone other than the Management Nominees listed herein.

as my/our proxyholder with full power of substitution and to attend, act and to vote for and on behalf of the shareholder in accordance with the following direction (or if no directions have been given, as recommended by management) and all other matters that may properly come before the **Annual General Meeting** of shareholders of **Aurinia Pharmaceuticals Inc.** to be held at 1200 Waterfront Centre, 200 Burrard Street, Vancouver, British Columbia on Thursday, June 21, 2018 at 9:00 am Pacific Time and at any adjournment or postponement thereof.

VOTING RECOMMENDATIONS ARE INDICATED BY **HIGHLIGHTED TEXT** OVER THE BOXES.

	For	Against
1. Number of Directors	<input type="checkbox"/>	<input type="checkbox"/>

To fix the number of directors to be elected at **eight (8)**.

2. Election of Directors			Fold
	For	Withhold	
01. Richard M. Glickman	<input type="checkbox"/>	<input type="checkbox"/>	
02. Lorin J. Randall	<input type="checkbox"/>	<input type="checkbox"/>	
03. Benjamin Rovinski	<input type="checkbox"/>	<input type="checkbox"/>	
04. David R.W. Jayne	<input type="checkbox"/>	<input type="checkbox"/>	
05. George M. Milne, Jr.	<input type="checkbox"/>	<input type="checkbox"/>	
06. Hyuek Joon Lee	<input type="checkbox"/>	<input type="checkbox"/>	
07. Joseph P. Hagan	<input type="checkbox"/>	<input type="checkbox"/>	
08. Michael Hayden	<input type="checkbox"/>	<input type="checkbox"/>	

	For	Withhold
3. Appointment of Auditors	<input type="checkbox"/>	<input type="checkbox"/>

Reappointment of PricewaterhouseCoopers LLP as auditors of the Company for the ensuing year and authorizing the audit committee to fix their remuneration.

Authorized Signature(s) - This section must be completed for your instructions to be executed.

I/We authorize you to act in accordance with my/our instructions set out above. I/We hereby revoke any proxy previously given with respect to the Meeting. **If no voting instructions are indicated above, this Proxy will be voted as recommended by Management.**

Signature(s)

Date

DD / MM / YY

Interim Financial Statements - Mark this box if you would like to receive Interim Financial Statements and accompanying Management's Discussion and Analysis by mail.

Annual Financial Statements - Mark this box if you would NOT like to receive the Annual Financial Statements and accompanying Management's Discussion and Analysis by mail.

If you are not mailing back your proxy, you may register online to receive the above financial report(s) by mail at www.computershare.com/maillinglist.



I S A Q

2 7 6 0 2 5

A R 2

